DF/HCC 20-614 Combinatons of Sacituzumab govitecan plus enfortumab vedotin and pembrolizumab for metastatic urothelial carcinoma: the Double Antibody Drug conjugate (DAD) and Double Antibody Drug Conjugate with Immunotherapy (DAD-IO) Phase I/II trial
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Sponsor
Dana Farber/Mass General BrighamCancerCare